Lilly makes fresh bet on IL-17 with $2.4B acquisition of Dice Therapeutics

Eli Lilly has taken a high-stakes gamble on oral IL-17 inhibitors, betting $2.4 billion upfront that acquiring Dice Therapeutics will expand its autoimmune arsenal.